3SBio Inc. (FRA:83B)

Germany flag Germany · Delayed Price · Currency is EUR
2.520
+0.020 (0.80%)
Last updated: Jan 28, 2026, 10:30 AM CET
245.21%
Market Cap6.27B +271.7%
Revenue (ttm)1.08B +7.7%
Net Income280.34M +42.2%
EPS0.11 +40.7%
Shares Outn/a
PE Ratio22.37
Forward PE8.24
Dividend0.03 (1.06%)
Ex-Dividend DateJul 21, 2025
Volumen/a
Average Volume8
Open2.540
Previous Close2.500
Day's Range2.520 - 2.540
52-Week Range0.720 - 3.880
Betan/a
RSI34.14
Earnings DateMar 20, 2026

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1993
Employees 6,268
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 83B
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements